Kane Biotech Inc (KNE) — Capital Reinvestment Ratio

Latest as of June 2023: 0.15x

Kane Biotech Inc (KNE) has a Capital Reinvestment Ratio of 0.15x as of June 2023, meaning it reinvests 0% of its operating cash flow (CA$382.38K) in capital expenditures (CA$58.65K). See Kane Biotech Inc (KNE) balance sheet quality index to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.15x

Capex / Operating Cash Flow

Operating Cash Flow

CA$382.38K

CAD

Capital Expenditures

CA$58.65K

CAD

Data as of

Jun 2023

Most recent filing

Annual Capital Reinvestment Ratio for Kane Biotech Inc (None–None)

Year-by-year Capital Reinvestment Ratio for Kane Biotech Inc from None to None. For live market cap and broader valuation context, see KNE market cap overview.

Year	Reinvestment Ratio	Operating CF (CAD)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow